CellSource Co., Ltd. (4880.T)
JPY 621.0
(-2.36%)
JPY 621.0
(-2.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.96 Billion JPY | 31.49% |
| 2022 | 1.49 Billion JPY | 38.06% |
| 2021 | 1.08 Billion JPY | 28.24% |
| 2020 | 843.4 Million JPY | 2.03% |
| 2019 | 826.65 Million JPY | 42.32% |
| 2018 | 580.83 Million JPY | 312.63% |
| 2017 | 140.76 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 585.47 Million JPY | 4.93% |
| 2024 Q1 | 557.94 Million JPY | -3.03% |
| 2024 Q3 | 588.33 Million JPY | 0.49% |
| 2023 Q3 | 504.8 Million JPY | 10.92% |
| 2023 FY | 1.96 Billion JPY | 31.49% |
| 2023 Q4 | 575.39 Million JPY | 13.98% |
| 2023 Q2 | 455.11 Million JPY | 6.29% |
| 2023 Q1 | 428.17 Million JPY | 8.53% |
| 2022 Q4 | 394.52 Million JPY | 0.35% |
| 2022 FY | 1.49 Billion JPY | 38.06% |
| 2022 Q2 | 368.6 Million JPY | 9.39% |
| 2022 Q1 | 336.95 Million JPY | 28.66% |
| 2022 Q3 | 393.16 Million JPY | 6.66% |
| 2021 Q2 | 268.52 Million JPY | -0.19% |
| 2021 Q1 | 269.02 Million JPY | 23.02% |
| 2021 Q3 | 282.13 Million JPY | 5.07% |
| 2021 Q4 | 261.89 Million JPY | -7.17% |
| 2021 FY | 1.08 Billion JPY | 28.24% |
| 2020 Q4 | 218.68 Million JPY | 1.99% |
| 2020 Q2 | 217.93 Million JPY | 13.3% |
| 2020 Q1 | 192.35 Million JPY | -8.89% |
| 2020 FY | 843.4 Million JPY | 2.03% |
| 2020 Q3 | 214.42 Million JPY | -1.61% |
| 2019 FY | 826.65 Million JPY | 42.32% |
| 2019 Q4 | 211.11 Million JPY | 0.0% |
| 2018 FY | 580.83 Million JPY | 312.63% |
| 2017 FY | 140.76 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -52.864% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -240.403% |
| GNI Group Ltd. | 9.32 Billion JPY | 78.938% |
| Linical Co., Ltd. | 2.7 Billion JPY | 27.417% |
| Trans Genic Inc. | 2.15 Billion JPY | 9.09% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -31.676% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 36.065% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -5.736% |
| AnGes, Inc. | 8.9 Billion JPY | 77.944% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -108.2% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 89.768% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -375.435% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -101.308% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 23.527% |
| CanBas Co., Ltd. | 278 Million JPY | -606.294% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -72.005% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -8.006% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -22.431% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 17.294% |
| PeptiDream Inc. | 9.68 Billion JPY | 79.731% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -0.148% |
| Ribomic Inc. | 1.1 Billion JPY | -77.581% |
| SanBio Company Limited | 4.53 Billion JPY | 56.742% |
| Healios K.K. | 3.48 Billion JPY | 43.691% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -70.038% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -47.137% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -39.904% |
| StemRIM | 2.07 Billion JPY | 5.419% |
| FunPep Company Limited | 313.82 Million JPY | -525.674% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -104.955% |
| Stella Pharma Corporation | 963.98 Million JPY | -103.685% |
| TMS Co., Ltd. | 943.25 Million JPY | -108.162% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -80.145% |
| Cuorips Inc. | 598.11 Million JPY | -228.279% |
| K Pharma,Inc. | 543.94 Million JPY | -260.975% |
| Takara Bio Inc. | 23.9 Billion JPY | 91.786% |
| ReproCELL Incorporated | 1.51 Billion JPY | -29.688% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -65.837% |
| StemCell Institute Inc. | 1.16 Billion JPY | -68.958% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -28.984% |
| CellSeed Inc. | 804.93 Million JPY | -143.934% |